Sign in

CIK 0001789769

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

Instil Bio, Inc.

Sign in to watch
Ticker
TIL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
NY
Entity type
Operating
EIN
832072195
Phone
+1 972-499-3350
Business address
3963 MAPLE AVENUE, SUITE 350, DALLAS, TX, 75219
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2025-04-25 Crouch Bronson CEO and Chairman Grant or award · Employee Stock Option (right to buy) +105,157 105,157
2024-09-18 Crouch Bronson CEO and Chairman Grant or award · Employee Stock Option (right to buy) +50,000 50,000
2024-02-10 Crouch Bronson CEO and Chairman Grant or award · Employee Stock Option (right to buy) +120,000 120,000
2023-01-08 Crouch Bronson CEO and Chairman Grant or award · Employee Stock Option (right to buy) +1,000,000 1,000,000
2022-03-04 Crouch Bronson CEO and Chairman Grant or award · Employee Stock Option (right to buy) +750,000 750,000
2022-03-04 Crouch Bronson CEO and Chairman Grant or award · Employee Stock Option (right to buy) +750,000 $8.62 $6.5M 750,000
2021-05-11 Crouch Bronson CEO and Chairman Grant or award · Employee Stock Option (right to buy) +750,000 750,000
2021-03-23 Crouch Bronson CEO and Chairman Conversion +30,000,000 30,000,000
2021-03-23 Crouch Bronson CEO and Chairman Conversion +6,098,799 36,098,799
2021-03-23 Crouch Bronson CEO and Chairman Conversion +1,431,274 37,530,073
2021-03-23 Crouch Bronson CEO and Chairman Purchase +450,000 $20.00 $9.0M 37,980,073
2021-03-23 Crouch Bronson CEO and Chairman Conversion · Series A Preferred Stock −25,000,000 0
2021-03-23 Crouch Bronson CEO and Chairman Conversion · Series B Preferred Stock −5,082,333 0
2021-03-23 Crouch Bronson CEO and Chairman Conversion · Series C Preferred Stock −1,192,729 0
2021-03-18 Crouch Bronson CEO and Chairman Grant or award · Employee Stock Option (right to buy) +1,200,000 1,200,000

Page 1 of 1 · 15 trades